Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

AstraZeneca80 enrolled

Overview

The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study * Signed and dated Patient Informed Consent (ICF) Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

Locations (15)

Research Site

Bauska, Latvia

Research SIte

Cēsis, Latvia

Research Site

Daugavpils, Latvia

Research Site

Outcomes

Primary Outcomes

Improvement in CGI scores and BPRS comparing visits 1 and 3.

Time frame: twice with 4 week interval

Secondary Outcomes

To evaluate compliance to therapy

Time frame: twice with 4 week interval

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.